FHIT抗体

+ +

•  

   

     Gel: 8+12%SDS-PAGE, Lysate: 30 μg, Lane: Human fetal kidney tissue, Primary antibody: P07300(FHIT Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07300(FHIT Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The FHIT (fragile histidine triad) antibody is a crucial tool in studying the FHIT protein, encoded by the *FHIT* gene located on chromosome 3p14.2. This region is frequently altered in various cancers due to deletions, hypermethylation, or transcriptional silencing. The FHIT protein, a member of the histidine triad (HIT) family, is implicated in tumor suppression by regulating cell cycle progression, apoptosis, and genome stability. Its loss or reduced expression is linked to the pathogenesis of numerous cancers, including lung, breast, gastric, and cervical cancers.

FHIT antibodies are widely used in research to detect FHIT protein levels in tissues or cell lines via techniques like immunohistochemistry (IHC), Western blotting, or immunofluorescence. These studies aim to correlate FHIT expression with clinical outcomes, tumor progression, or therapeutic responses. Commercially available FHIT antibodies are typically raised against specific epitopes, such as recombinant protein fragments or synthetic peptides, and validated for specificity across human and model organisms.

Research utilizing FHIT antibodies has provided insights into its tumor-suppressive mechanisms, including interactions with stress granules, DNA repair pathways, and metabolic enzymes. Additionally, FHIT restoration strategies, such as gene therapy or demethylating agents, are being explored as potential cancer treatments. Despite challenges in standardizing antibody performance across assays, FHIT remains a biomarker of interest for early cancer detection and prognosis.